Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study

Table 1 Study overview; patient demographics and disease characteristics

Baseline patient description
	Number	Mean	SD
Patient characteristics
Age, years, SD	740	52.5	12.3
Body mass index, kg/m²	732	27.9	6.5
Disease duration, years	740	9.6	8.2
Health assessment questionnaire	676	1.5	0.6
Pain, 100 mm visual analogue scale	733	54	22
Disease activity score in 28 joints	726	6.5	0.93
Biomarker measures
C-reactive protein, mg/L	740	2.10	2.48
C1M, nmol/L	585	109	72
C2M, nmol/L	626	0.553	0.193
C3M, nmol/L	599	43.2	22.6
CRPM, nmol/L	599	17.1	8.39
Matrix metalloproteinase 3, ng/mL	676	54.3	60.5
Osteocalcin, nmol/L	671	21.7	13.6
CTX-I, nmol/L	671	0.413	0.201
CTX-I/OC ratio	671	0.023	0.0136

CIM, C2M, C3M matrix metalloproteinase-derived fragments of type I, type II and type III collagen, CRPM degradation fragment of C-reactive protein, CTX C-terminal telopeptide of type I collagen

ISSN: 1478-6362